

## **BioLight announces that the subsidiary IOptima received regulatory approval for the marketing and sale of the IOptiMate™ system in China**

Tel Aviv, Israel, March 2, 2014: **BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT)** announces today that the subsidiary IOptima (87.17%) notified it that the China Food and Drug Administration (the CFDA) approved the marketing and sale of the IOptiMate™ system in China.

The IOptiMate™ system developed by IOptima, one of Bio Light's eye cluster companies, is based on CO<sub>2</sub> laser technology that enables the performance of a unique filtration surgery for treatment of glaucoma without invading the inner part of the eyeball.

The IOptiMate™ system was registered in China through China Meheco Co, Ltd. a company incorporated under the laws of the People's Republic of China. China Meheco Co. is also expected to perform the import activity into China. For the purpose of commencement of sales, IOptima is acting to enter in the near future into engagements with third parties that will serve as distributors of the IOptiMate™ system in China.

IOptima intends to officially launch the IOptiMate™ system in China at the International Congress of Ophthalmology and Optometry (the COOC) to be held at the end of March 2014.

### **Forward-Looking Statements**

This press release contains forward looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us and our affiliate companies. There can be no assurance that such results will be realized and actual results in each case could differ materially from those currently anticipated in such statements as a result of various factors. BioLight is not under any obligation to update or correct any future forecasts and/or forecasting statements to reflect events or circumstances after the date of this press release. BioLight makes no express or implied representation or warranty as to the achievement of the forecasts or the accuracy or completeness of the information contained herein. BioLight expressly disclaims any and all liability which may be based on such information, errors therein or omissions therefrom. This press release does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or sell securities of BioLight